Becton Dickinson and Co vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Becton Dickinson and Co trades at $156.09 (market cap $41.51B), while Direxion Daily S&P 500 Bull 3X Shares trades at $277.79. The key difference: Becton Dickinson and Co pays a 2.79% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | SPXL | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.39 | $288.04 |
52-Week Low | $135.49 | $170.20 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
SPXL is trading at $272.66, down 2.34% today, with a bullish technical signal supported by moving averages. The stock faces resistance at $277-$283 while finding support at $270-$264 levels. Recent news highlights ongoing AI-driven market dynamics and earnings season catalysts that could influence S&P 500 performance.
Outlook remains cautiously optimistic with technical strength but requires monitoring of earnings results and market sentiment. Key risks include stretched valuations and potential market volatility during earnings season. The stock's performance remains tied to broader S&P 500 trends and AI sector developments.
Trailing returns across standard periods
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →